Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

NCT02756962 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

107

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Cytarabine
PROCEDURE: Allogeneic stem cell transplant
PROCEDURE: Bone marrow aspiration
PROCEDURE: Punch skin biopsy
DEVICE: ClinSeq

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]